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ABSTRACT
Motivation: One of the most deadly cancer diagnoses is the
carcinoma of unknown primary origin. Without the knowledge of
the site of origin, treatment regimens are limited in their speciﬁcity
and result in high mortality rates. Though supervised classiﬁcation
methods have been developed to predict the site of origin based
on gene expression data, they require large numbers of previously
classiﬁed tumors for training, in part because they do not account for
sample heterogeneity, which limits their application to well-studied
cancers.
Results: We present ISOLATE, a new statistical method that
simultaneously predicts the primary site of origin of cancers and
addresses sample heterogeneity, while taking advantage of new
high-throughput sequencing technology that promises to bring
higher accuracy and reproducibility to gene expression proﬁling
experiments. ISOLATE makes predictions de novo, without having
seen any training expression proﬁles of cancers with identiﬁed origin.
Compared with previous methods, ISOLATE is able to predict the
primary site of origin, de-convolve and remove the effect of sample
heterogeneity and identify differentially expressed genes with higher
accuracy, across both synthetic and clinical datasets. Methods such
as ISOLATE are invaluable tools for clinicians faced with carcinomas
of unknown primary origin.
Availability: ISOLATE is available for download at:
http://morrislab.med.utoronto.ca/software
Contact: gerald.quon@utoronto.ca; quaid.morris@utoronto.ca
Supplementary information: Supplementary data are available at
Bioinformatics online.
1 INTRODUCTION
While most cancerous tumors present at their cancer site of origin
(CSO), ∼4% of all new tumors do not (American Cancer Society,
2001). Without knowledge of this site, treatment regimens are
highly limited in their speciﬁcity and result in high mortality rates
(Blaszyk et al., 2003; Shaw et al., 2007). In an effort to identify
CSO, patients routinely undergo extensive clinical examination,
radiology and histoimmunological testing (Hainsworth and Greco,
1993). However, these drastic interventions fail to identify the site
of origin more than half of the time (Blaszyk et al., 2003).
∗To whom correspondence should be addressed.
Gene expression proﬁling provides a precise, high-resolution
molecular ﬁngerprint of a tumor that also offers insight into the
underlying transcriptional activity that gave rise to its aberrant
behavior (Liotta and Petricoin, 2000). To date, a number of
supervised classiﬁcation methods have been used to categorize
tumors according to their site of origin based on gene expression
proﬁles, including support vector machines (Ramaswamy et al.,
2001; Su et al., 2001; Tothill et al., 2005), decision trees (Dennis
etal.,2005;Sheddenetal.,2003),K-nearestneighbors(Bridgewater
et al., 2008; Giordano et al., 2001; Horlings et al., 2008), neural
networks (Bloom et al., 2004) and others (Buckhaults et al., 2003;
Dennis et al., 2002; Varadhachary et al., 2008).
Thesestudiesallshareasimilarthree-stepstrategy:transcriptional
proﬁles of many tumors with known sites of origin are used
to identify individual marker genes whose expression levels
discriminate cancers of different origin; then the expression levels
of these marker genes in each tumor are used to train a classiﬁer that
is subsequently used to classify new tumors not previously labeled
with a site of origin.
These microarray-based models have shown great diagnostic
potentialforidentifyingthesiteoforiginofpatientswithcarcinomas
of unknown primary origin: accuracies of >80% were commonly
reported for some types of carcinomas. However, because these
methods are supervised classiﬁcation methods, they require large
amounts of transcriptionally proﬁled tumors with identiﬁed origin
upon which to train. While this data may be available for mature
tumors from common sites of origin, there are many less well-
characterized cancers or poorly differentiated tumors that often
have very little or no data available upon which to train. Reported
prediction accuracy on these underrepresented tumors is little better
than random performance (Ramaswamy et al., 2001; Shedden et al.,
2003; Su et al., 2001). Classiﬁer performance also depends critically
on the CSO-speciﬁc marker genes identiﬁed in the preprocessing
step, making downstream analysis highly sensitive to the marker
set (Tothill et al., 2005). Unsupervised methods that neither rely on
previously collected training data nor prescreen for marker genes
are therefore of high value. However, to the best of our knowledge,
such methods are not currently available.
It is often of interest to not only identify the site of origin, but
also to identify the genes differentially expressed in the cancer cells
with respect to the site of origin. Ideally, the tumor expression
proﬁle can be directly compared with that of the CSO to identify
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Fig. 1. Multiple samples taken from even the same tumor can be
composed of different mixing proportions of component sources, giving
rise to signiﬁcantly different tumor expression proﬁles compared with the
expression proﬁle of the homogeneous cancer cell population. Methods
for de-convolving sample heterogeneity and removing the contributions of
non-cancerous cell populations to the measured expression proﬁle aim to re-
construct the expression proﬁle of the homogeneous cancer cell population.
those differentially expressed genes. However, tumors are not
homogeneous masses of cancer cells, but are mixtures of cell
populations with varying levels of heterogeneity, not only between
tumors of the same cancer but also even across the samples from the
same tumor (Dennis et al., 2005). Contaminating cell populations
can include surrounding healthy tissues (such as the site of origin or
the local site of a metastatic tumor) and supporting stroma (Masters
and Lakhani, 2000). Sample heterogeneity contributes signiﬁcantly
to the large diversity of expression proﬁles observed even from
similar tumor samples, and in many cases contaminating non-cancer
cells can dominate the expression proﬁle (Golub et al., 1999; Liotta
and Petricoin, 2000; Reya et al., 2001), as illustrated in Figure 1.
While methods exist for de-convolving heterogeneous expression
proﬁles into their individual component proﬁles and inferring
the so-called mixing proportions (also known as coefﬁcients),
based on techniques like Independent Components Analysis (ICA)
(Hyvarinen, 2001; Lahdesmaki et al., 2005; Venet et al., 2001), they
have been developed independently of the models for identifying
CSO and therefore are currently applied as a preprocessing step.
The advent and rapidly decreasing cost of high-throughput
sequencing (HTS) methods for expression proﬁling promises much
higher reproducibility and a wider dynamic range of detectable
gene expression than microarrays (Marioni et al., 2008; Mortazavi
et al., 2008). HTS methods are quickly becoming feasible for highly
accurate characterization of the transcriptome proﬁle of tumors.
However, the digital counting of sequence tags in HTS methods
leads to a different observation of noise process compared with the
analog measurement of probe intensity in microarrays. This change




that simultaneously identiﬁes sites of origin in an unsupervised
fashion and addresses sample heterogeneity using HTS cancer
expression proﬁling. ISOLATE is designed to achieve three goals:
identiﬁcation of the site of origin from a set of proﬁled candidate
sites, de-convolution of heterogeneous expression proﬁles into
their individual components and identiﬁcation of differentially
expressed genes. We demonstrate on both synthetic and clinical
datasets that ISOLATE achieves higher accuracy on all of
these goals than a similar ICA-based unsupervised strategy that
mirrors existing tools. The high accuracy levels achieved by
ISOLATE demonstrate the feasibility of unsupervised methods
for complementing traditional immunohistological and supervised
classiﬁcation models for identifying the site of origin of and
characterizing tumors from carcinomas of unknown primary origin.
2 APPROACH OVERVIEW
ISOLATE is designed to achieve three goals, illustrated in Figure 2:
identiﬁcation of the CSO, identiﬁcation of the differentially
expressed genes in the homogeneous cancer cell population and
characterization of the cellular composition of each heterogeneous
tumor sample (by estimation of the mixing proportions of their
component cell populations). We compared ISOLATE with an ICA-
based strategy that can be applied using existing tools to address the
three challenges. In this study, we use Latent Dirichlet Allocation
(LDA) (Blei et al., 2003) to implement the ICA strategy. LDA is
an equivalent model to ICA (Shashanka et al., 2008) but with an
observation noise model more appropriate for digital HTS data.
Both ISOLATE and LDA model the expression proﬁle of a
heterogeneous tumor sample as a weighted mixture of expression
proﬁles of ‘source’ cell populations (representing candidate sites
of origin or contaminants), all of which have been previously
characterized except for the homogeneous cancer cell population.
The set of source cell populations are herein called the ‘Source
Panel’. Candidate sites of origin and potential contaminating cells
can be treated similarly in the context of LDA and ISOLATE and
are hence both referred to as sources. ISOLATE differs from LDAin
thatitexplicitlymodelsthesimilaritiesinexpressionproﬁlebetween
the cancer cell population and the site of origin by representing
the homogeneous cancer expression proﬁle as a sparsely perturbed
version of the proﬁle of its site of origin. Tumor cells display
functional, developmental and morphological similarities to their
site of origin (Lobo et al., 2007; Sell and Pierce, 1994). This
similarity is also reﬂected at the gene expression level, both between
the primary tumor and the site of origin (Khan et al., 2001;
Ross et al., 2000), and between the primary and metastatic tumor
(D’Arrigo et al., 2005; Weigelt et al., 2003). By explicitly modeling
the cancer cell expression proﬁle as a perturbation of the site of
origin proﬁle, our model is a more precise representation of cancer
that naturally leads to the identiﬁcation of differentially expressed
genes as those whose expression was perturbed to produce the
tumor expression proﬁle. ISOLATE then uses the estimate of the
homogeneous cancer proﬁle in conjunction with the Source Panel
to decompose each tumor sample.
A key feature of ISOLATE is that it recognizes the
interdependence of the solutions of all three goals and iteratively
solves all of them simultaneously. In contrast, the ICA strategy
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Fig. 2. Outline of the ISOLATE and LDAmethods for de-convolving cancer gene expression data and identifying the site of origin. The input to each method
consists of the expression proﬁle of a heterogeneous tumor sample(s), as well as the Source Panel representing previously proﬁled cell populations that may
act either as contaminants or as candidate sites of origin. Each method performs three tasks: identiﬁcation of the site of origin, identiﬁcation of those genes
differentially expressed in the cancer cells and characterization of the cellular composition of each heterogeneous sample by estimating the mixing proportions
of each component cell population. The ICA-based strategy operates serially by ﬁrst de-convolving the heterogeneous sample without constraining the cancer
proﬁle to be derived from the Source Panel, then predicts the site of origin and differentially expressed genes. This is in stark contrast to ISOLATE, which
solves all three problems cooperatively.
ﬁrst iteratively decomposes the tumor samples while estimating the
proﬁleofthehomogeneouscancercellpopulation.Thenitcompares
the estimated homogeneous cancer proﬁle to the Source Panel and
identiﬁes the parent site as the most similar proﬁle, and ﬁnally
identiﬁes differentially expressed genes by comparing the estimated
cancer proﬁle to that of the identiﬁed site of origin. This makes
the ICA-based strategy for identifying the site of origin sensitive to
imperfect de-convolution of the tumor expression proﬁles and often
leads to misidentiﬁcation of the site of origin as the surrounding
tissue.
The following sections describe how we generated the synthetic
datasets and collected and processed the clinical datasets that we
used to test our model. We also describe statistical inference with
ISOLATE and LDA.
3 METHODS
3.1 Synthetic data collection
We measured the performance of ISOLATE on a comprehensive set of
synthetic data for which the correct answer is known. Our strategy for
generating data is shown in Figure 3 and summarized below, with more
details provided in following sections. Each experiment is deﬁned by ﬁve
parameters: the number of genes whose expression is perturbed in the cancer
cells, their multiplicative perturbation factor, the number of heterogeneous
tumor samples proﬁled, the number of sources in the Source Panel and the
level of biological variability of the expression proﬁles of the same sources
between different cancer patients. First, using human kidney and liver data
from Marioni et al. (2008), we generate expression proﬁles for each source,
both for the (a) training proﬁles that make up the Source Panel, and (b)
for a template healthy patient. From the template healthy patient, (c) we
Fig.3. Overallexperimentalstrategyforgeneratingtheheterogeneoustumor
samples from three sources (i.e. candidate sites of origin) to input into the
LDAand ISOLATE models. The sources color-matched between the Source
Panel and the template healthy patient differ only by technical variability
in their expression proﬁles. Yellow represents cancer cells, while orange
represents the site of origin.
randomly select one component source as the site of origin, from which we
perturb the expression proﬁle to construct a cancer cell expression proﬁle.
The original template of healthy source expression proﬁles together with the
cancer cell expression proﬁle make up a template cancer patient, from which
we (d) generate one or more unique cancer patients by adding variability
to the template cancer patient independently for each cancer patient. (e)
One heterogeneous tumor sample is generated from each individual using
a unique set of mixing proportions to combine the source proﬁles of the
cancer patient. Finally, we use the Source Panel and the heterogeneous tumor
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samples as input into the LDA and ISOLATE models, to (f) identify the
CSO, (g) de-convolve the heterogeneity of each tumor sample, and identify
differentially expressed genes.
3.1.1 Dataset Human liver and kidney transcriptome proﬁling data from
a single human male was obtained from Marioni et al. (2008) who sequenced
each tissue seven times, split across two runs of an Illumina Genome
Analyzerandattwoconcentrations,1.5pMand3pM.Allreadsweremapped
to the genome using the Illumina ELAND algorithm, and only uniquely
mapped reads were retained. A gene copy number is computed by counting
the number of reads mapped to each known transcript, then computing the
median number of copies for each gene over all of its respective transcripts.
We discarded all genes for which there was not even one copy in all of the
runs of both tissues, leaving 13061 genes. Gene abundances (also called
the expression proﬁle) were computed from gene copy numbers by dividing
each copy number by the sum of all gene copy numbers.
3.1.2 Generating a new source expression proﬁle We ﬁrst applied a
differential expression test (Lu et al., 2005) to identify the top 40% of all
genes that were most likely to be constitutively expressed across all of the
kidney and liver datasets and deemed these to be candidate house-keeping
genes (Zhu et al., 2008). We then randomly selected two runs from either
the kidney or liver datasets, and permuted the expression levels of their
non-house-keeping genes randomly in the same order. One run is used in
the Source Panel (Fig. 3a) as previously proﬁled abundances in LDA and
ISOLATE,whiletheotherisusedinthetemplatehealthyindividual(Fig.3b).
3.1.3 Generating a cancer cell expression proﬁle To generate a cancer
cell expression proﬁle given the expression proﬁle of the site of origin, the
number of genes to perturb and their perturbation factor, we ﬁrst randomly
selected the set of genes to become differentially expressed, then randomly
perturbed the abundances of each gene in that set either up or down (with
equal probability), then renormalize the abundances to sum to 1 to make
gene abundances correspond to parameters of a multinomial distribution.
This cancer expression proﬁle and the healthy tissue proﬁles in the template
healthyindividualcombinetomakethesourcesinthetemplatecancerpatient
(Fig. 3c).
3.1.4 Generating a cancer patient from the template cancer patient We
use the template cancer patient to obtain a cancer patient proﬁle by
adding biological variability to each source expression proﬁle. We represent
biological variability by resampling the expression levels of a fraction of
genes from the entire set of expression levels observed in that source’s
original expression proﬁle. The expression proﬁle is subsequently rescaled
to sum to 1.
3.1.5 Generating a heterogeneous tumor sample from a cancer patient
We ﬁrst determine what proportion of each source will compose the tumor
sample, then we generate the sequence reads that are observed in the sample.
For the tumor sample d, the mixing proportions of the sources θd are drawn
from a Dirichlet distribution with parameters α={αsc,αs1,αs2,...,αsS},
where sc indicates the cancer source. In our experiments, for all non-cancer
sources i =c, αsi =1, and αsc =3 by default. Larger values of αsc will result
in tumor samples containing larger proportions of cancer cells. Once the
mixing proportions θd are generated, for each transcript read to generate, we
randomly select a source using the mixing proportions θd, then randomly
select a transcript from which to generate a read using the multinomial
distribution speciﬁed by the expression proﬁle of the chosen source. Each
tumor sample was generated with 1675078 reads, the average number of
reads collected per experiment in Marioni et al. (2008), though the results
were not sensitive to the total number of reads generated per tumor sample
(data not shown).
3.2 Clinical data processing
Both the ISOLATE and LDAstrategies require a fully proﬁled Source Panel
and heterogeneous tumor samples, but owing to the current lack of such
data available, we took advantage of the vast quantities of microarray data
available and chose to digitize such datasets to make them compatible with
our model. We downloaded a total of 93 tumor expression proﬁles from
Su et al. (2001), consisting of 10 kidney, 6 liver, 24 lung, 23 ovary, 6
pancreatic and 24 prostate-originating tumors collected using Affymetrix
U95a GeneChip arrays. Following the procedure of Su et al. (2001), for
each tumor sample, raw intensity values were thresholded at 20. Mappings
from the probe identiﬁer to Ensembl gene identiﬁers were downloaded from
the Affymetrix web site, and multiple probes matching the same Ensembl
gene identiﬁer were averaged together to produce a single measurement for
each gene. The resulting array intensities were rounded to the nearest integer
and treated as transcript counts from a HTS experiment.
As a Source Panel, we downloaded a separate set of microarray data
collected usingAffymetrix Human Genome U133Aarrays (Su et al., 2004),
giving us a healthy proﬁle version of those same six tissues. Intensities for
replicate array measurements were averaged together for each respective
tissue, and using the provided annotation ﬁles, each probe was mapped to its
respective Ensembl gene identiﬁer, and multiple probes matching the same
Ensembl gene identiﬁer were averaged together.
The total set of common genes proﬁled in the Source Panel and the
tumor proﬁles were 8667 genes. For these 8667 genes, their raw averaged
intensities in each source of the Source Panel were divided by the total
intensity measured to produce a proper multinomial distribution over the
proﬁled genes.
3.3 Inference with the LDA model
The input to the LDA model (Blei et al., 2003), for both the synthetic and
clinical datasets, consists of the expression proﬁles over all the genes in
each source. Each proﬁle is represented by a vector from the set {βs}S
s=1
that contains one vector for each of the S sources from the Source Panel.
Also input to the LDA model are D sets of reads {td,n}D
d=1 originating from
transcriptome proﬁling experiments of D heterogeneous tumor samples that
eachgenerateNd reads.LDAestimatestheexpressionproﬁleβsc ofallgenes
in the cancer source sc and performs de-convolution by inferring hidden
variables {zd,n} (one for each read td,n) that indicate from which of the
S+1 sources (S from the Source Panel, and 1 from the cancer source) the
transcript most likely originates. In doing so, LDA estimates the fraction of
each cancer sample d (the mixing proportions), θd,s, coming from each of




The model was trained using the same variational Expectation Maximization
(EM) framework used in Blei et al. (2003) with 100 iterations, and rerun S
times with random parameter initializations. The initialization that resulted
in the highest log likelihood of the data is chosen. The model parameters
estimated include α, θd for all tumor samples d, and cancer abundances
βsc. Using the output of LDA, we predict the site of origin by choosing
the source (from the Source Panel) whose expression proﬁle has the least
Kullback–Liebler divergence from the estimated cancer expression proﬁle
βsc. To rank genes in order of differential expression, we applied a two-class
differentialexpressiontest(Luetal.,2005)tocomparetheexpressionproﬁle
of the predicted site of origin against the set of reads the cancer cells are
responsible for in each tumor sample (zd,n=sc), and sorted the genes based
on the resulting P-value. Lastly, the mixing proportions (heterogeneity) of
each sample d are estimated directly from the learned parameters of the
model, θd.
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3.4 Inference with the ISOLATE model
ISOLATE maintains the same probabilistic framework as LDA [Equations
(1– 3)], but introduces the following key constraints on the learned
parameters βsc, where β:,g is a column vector of abundances of gene g





the site of origin. ρg is the estimated perturbation (multiplicative) factor that
describes how much the cancer cells perturb the expression of gene g relative
to the site of origin described by ω. Since we expect many genes to maintain
similar expression levels to that of the CSO, we put a Gamma prior on ρg
[Equation(5)],withmeanE[ρg]=1toemphasizethatweexpectmanygenes
to not have perturbed expression. ISOLATE uses the same variational EM
framework as LDA(Blei et al., 2003) with 100 iterations, and rerun using S
different initializations to test different candidate CSO. There is exactly one
initialization per source s where the value ωs is set to 1, and the remaining
entries set to 0. The initialization that resulted in the highest log likelihood
of the data is chosen. To rank genes in order of differential expression, we
sorted the genes based on the distance of ρg from the value 1. That is, the
farther ρg is from 1, the more perturbed its abundance is from that of the site
of origin. Finally, mixing proportions of each sample d is estimated directly
from the learned parameters of the model, θd.
3.5 Performance metrics
The error rate in identifying the primary site of origin is the fraction of
experiments in which the CSO was incorrectly identiﬁed. For the synthetic
datasets, the reported error is averaged over the 20 datasets generated for
each speciﬁc setting of the parameters. The model heterogeneity error is
computed by averaging, over all tumor samples, the mean absolute error of
the mixing proportions θd of the cancer cells and the true site of origin. We
only measure the error with respect to these two sources because we found
that almost all of the error in the mixing proportion estimates is from these
two sources. Finally, we assess the error of the identiﬁcation of differentially
expressed genes for the synthetic datasets by using the ranks of the genes (in
orderofdifferentialexpressionasdeﬁnedbyeachmodel)andourknowledge
of which genes are truly differentially expressed to compute an area under
the receiver operator curve (ROC), where larger values correspond to higher
accuracy. Error is computed as [1−(Area under ROC)].
4 RESULTS
4.1 Synthetic datasets
We have evaluated the relative performance of ISOLATE and LDA
as a function of realistic parameter settings to demonstrate their
robustness to different conditions. We also compared naiveLu,
a simple method for identifying differentially expressed genes
by simply applying a differential expression test directly without
accounting for sample heterogeneity. We do these comparisons
because of the dearth of clinical data and the difﬁculties associated
with deﬁning gold standards therein. We are also able to query a
largervarietyofexperimentalconditions.Intheabsenceofanalytical
estimates of performance, which are likely impossible due to the
complexity of our models, these comparisons provide the best
support for our claims of improved performance over LDA.
We varied the following parameters: the number of differentially
expressed genes, the perturbation factor by which their expression
levels are differentially expressed in cancer, the number of
heterogeneous tumor samples, the number of sources in the Source
Panel, and the (biological) variability between our proﬁled Source
Panel and the corresponding proﬁles used to generate the tumor
samples (see Section 3). This variability represents the expected
differences between the normal source proﬁles in our Source
Panel, which will likely come from different individuals, and the
corresponding source proﬁles for the patient from which the tumor
sample is drawn. Biological variability, which could represent either
biological variation or technical noise, is a key parameter because
it limits our ability to detect differentially expressed genes, as
seen below. In the following, we vary only a single parameter
from the default; the default parameters we use are 100 perturbed
genes, 3 tumor samples, 10 sources, a perturbation factor of two,
perturbation scale prior κ=10 [see Equation (5)], and a biological
variabilityof0.16(16%),whichempiricallyleadsto∼14%ofgenes
differentially expressed, as measured by Lu et al. (2005). This level
of differential expression between simulated individuals is similar
to reported variation between unrelated individuals (Sharma et al.,
2005).
4.1.1 Identiﬁcation of differentially expressed genes One of the
principal objectives of identifying CSO is to identify genes that are
differentially expressed in the cancer cell population with respect to
healthy cells of the site of origin. We tested each models’ ability to
identify the differentially expressed genes, deﬁned as those genes
whose expressions were perturbed to differentiate the cancer source
from the site of origin source, and measured the performance by the
area under the ROC curve (see Section 3). Figure 4a demonstrates
that ISOLATE consistently achieves higher accuracy at identifying
differentially expressed genes than LDAacross all three parameters
at almost all settings. Surprisingly, the performance of both LDA
and ISOLATE seem to stay constant despite increasing the number
of tumor samples available. Figure 5a illustrates that beyond a
variability level of 15%, increasing the amount of data does not
improve ISOLATE performance. Because 15% is near the average
variability between unrelated individuals (Sharma et al, 2005),
this result suggests that ISOLATE’s identiﬁcation of differentially
expressed genes can be improved by analyzing multiple tumor
samples from the same individual but not necessarily by analyzing
multiple samples from different individuals. Both ISOLATE and
LDA improve performance as the perturbation factor increases—a
direct result of its increasing differentiation from the site of origin
source and hence easier de-convolution of sample heterogeneity—
though ISOLATE improves at a much faster rate. The performance
of naiveLu, which does not address heterogeneity, illustrates that
de-convolution clearly improves the identiﬁcation of differentially
expressed genes. The ISOLATE performance gain over LDA is not
just simply due to a difference in the speciﬁc method that ISOLATE
uses to compute differential expression: we computed differential
expression using the same method as for LDA (ISOLATE-Lu) and
see that its performance is still better than LDA in many cases.
4.1.2 Identiﬁcation of CSO Figure 4b compares LDA and
ISOLATE based on how often they are able to correctly identify
the site of origin. ISOLATE consistently outperforms LDA across
all datasets. Most importantly, while ISOLATE is robust against
the number of sources in the Source Panel, the performance
of LDA diminishes rapidly after six sources. This makes LDA
and other ICA-like techniques impractical for considering many
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Fig. 4. Performance of ISOLATE and LDA on synthetic datasets. Each
row represents a different parameter tuned: the number of heterogeneous
tumor samples, the number of sources (non-cancer) in the Source Panel and
the perturbation factor of the differentially expressed genes (manipulating
the number of perturbed genes within the range of 50–500 genes did not
result in changes in performance to either model and are not shown). Each
column represents a different performance metric applied to each dataset. (a)
Differential expression error, (b) origin error and (c) heterogeneity error are
as deﬁned in Section 3. Two additional models are plotted in (a): ISOLATE-
Lu is the performance achieved when applying the same method as ICA
for identifying differentially expressed genes (Lu et al., 2005) to the output
of the ISOLATE model, and naiveLu is the performance achieved when
directly comparing the heterogeneous tumor expression proﬁles to the site
of origin to identify differentially expressed genes, without accounting for
sample heterogeneity.
potential candidates for the CSO, an important feature given the
potentially large set of candidate CSO to query. The difference
between ISOLATE and LDA also illustrates the improvement in
CSO identiﬁcation, sometimes as staggeringly as 70%, achieved
by solving for both cell population mixture coefﬁcients and CSO
simultaneously within the same framework. From Figure 5b, we
see that ISOLATE achieves high accuracy at identifying CSO under
even high variability conditions, while LDA accuracy varies quite
widely even under low variability conditions. ISOLATE is therefore
abletocapturetheunderlyingsignalofthesiteoforiginevendespite
large amounts of noise in the expression proﬁles. Most importantly,
even when looking at very small sets of tumor samples, ISOLATE
performs as well as it does with many more samples, an important
feature given the cost of proﬁling tumors in a diagnostic setting.
4.1.3 Correction of sample heterogeneity Figure 4c illustrates
that when considering Source Panels containing fewer than 10
proﬁles, ISOLATE achieves better de-convolution of heterogeneity
thanLDA.However,theirperformanceisnearlyidenticalregardless
of the perturbation factor applied to the differentially expressed
genes, suggesting that the amount of tumor sample data is far
more important for de-convolution than the difference in expression
proﬁles of the cancer cells and the site of origin. As expected, as
Fig. 5. Performance of ISOLATE and LDA on synthetic datasets under
differentbiologicalvariabilityconditions.Eachcolumnrepresentsadifferent
performance metric, and each row a different model (top, ISOLATE; bottom,
LDA). Here, we co-vary the biological variability added to each tumor
sample independently, and the number of tumor samples made available
to each model. The performance metrics of (a) differential expression error,
(b) origin error and (c) heterogeneity error are as deﬁned in Section 3.
Fig. 6. An example of heterogeneity error for a single tumor sample. Here,
we illustrate a representative tumor sample whose mixing proportions of
componentsourceswereestimatedbyISOLATE(toprow)andLDA(bottom
row),comparedwiththeactualvalues(middlerow).Eachofthefourcolumns
on the left represent a source from the Source Panel (Sources 1–3, as well
as the site of origin source), while the right-most ﬁfth column represents the
cancer cells. The area of each square is proportional to the fraction of the
sample composed of that particular source. Whereas ISOLATE estimated
mixing proportions fairly close to the truth, the LDA estimate of the CSO
and cancer sources were quite erroneous.
the number of tumor samples increases, both LDA and ISOLATE
increase in performance. Figure 5c illustrates that ISOLATE
achieves better accuracy for the same number of data points and
level of variability, although it takes more samples for a given
level of biological variability than LDA to achieve its maximum
performance. Most of the performance loss in LDA appears to be
due to confusion of the contributing expression signatures from
the cancer cells and the site of origin source (Fig. 6 illustrates
an example). This is a problem that ISOLATE is able to mitigate
because of the constraints it places on the learned cancer expression
proﬁle.
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Fig. 7. The performance of ISOLATE, LDA and another Kullback-Leibler
(KL) divergence-based measure on the clinical dataset of 93 tumor samples.
Each sample is predicted independently of all other samples in the dataset.
The number of samples in each class is shown beside the class name, and
classes are in decreasing order of size, from left to right, with the overall
performance shown in the leftmost column. The black line shows random
performance.
4.2 Clinical dataset
We used ISOLATE and LDA to predict the site of origin of 93
tumor samples from Su et al. (2001). Heterogeneity and differential
expression error could not be measured on these datasets as the true
values are not known. Each tumor, regardless of its site of origin,
is predicted independently of all other tumors, to reproduce clinical
diagnosticconditions.AsabenchmarkbesidesLDA,weconstructed
a predictor that chooses the source from the Source Panel whose
Kullback-Leibler (KL)-divergence is least with respect to the tumor
sample’s expression proﬁle (KL). To set the perturbation scaling
prior κ of Equation (5), we tried several values of κ (100,1 0 1,1 0 2,
103,1 0 4,1 0 5), and performed 2-fold cross-validation by choosing
theκ thatmaximizedperformanceofhalfthedata,inordertopredict
the other half of the dataset, and vice versa. The optimal value of κ
was 105 for both halves of multiple splits of the data, and so was
usedtogeneratetheresultsshowninFigure7.Overtheentiredataset
of 93 tumor samples, ISOLATE achieves the highest performance
of 65.59% accuracy, compared with 52.69% of both LDA and the
KL measure. On a class-by-class basis, ISOLATE ties or performs
betterthanLDAandISOLATEinthelargerclasses,onlyperforming
worse when predicting tumors originating from the pancreas, the
smallest class. Note that though previously reported performance of
supervised classiﬁcation methods is higher on some of these cancer
types, ISOLATE achieves the observed performance considering
each tumor separately without reference to any of the other tumor
samples and without any training, mirroring clinical settings for the
CSO identiﬁcation of tumors underrepresented among previously
proﬁled samples.
5 DISCUSSION
We have developed ISOLATE to provide a molecular diagnostic
tool to aid in identifying the site of origin of tumors of poorly
characterized cancers, situations in which classical supervised
models perform poorly. ISOLATE simultaneously de-convolves
tumor expression proﬁles, and identiﬁes the CSO and genes
differentially expressed in the cancer cells, three tasks that
were previously solved independently. Our experiments detail
the performance of ISOLATE under a wide range of realistic
experimental conditions for synthetic and digitized clinical
microarray data, showing that solving all three tasks simultaneously
leads to greater predictive performance than solving them
individually.
ISOLATE, unlike previous methods for classifying cancers of
unknownprimaryorigin,isanunsupervisedclassiﬁcationalgorithm,
which provides it with several inherent advantages. It does not
require a large training set of tumors of known primary origin, and
in our clinical validation we only use data from a single tumor,
a particularly important feature given the difﬁculty and cost of
procuring many high-quality tumor samples in a diagnostic setting.
Because it is an unsupervised algorithm, ISOLATE’s performance
is also less sensitive to the number of candidate sites of origin, as
suggested by our synthetic data validation, in contrast to supervised
learning methods that have difﬁculty with more than 10 classes (Su
et al., 2001). By its construction, ISOLATE is also less prone to
overﬁtting than supervised learning algorithms, and as such, does
notrequireaprescreeningstagetoidentifymarkergenesuponwhich
cancers could be discriminated.
Despite our use of microarray data for our clinical validation, we
recommendthatISOLATEbeusedexclusivelywithHTSexpression
proﬁles, which we believe support more accurate tumor diagnosis.
HTS methods promise a substantial reduction in sample-to-sample
variability, which our synthetic data-based validation shows limits
theaccuracy.Also,becauseHTSmeasurementsarenotprobe-based,
they are both less platform-speciﬁc, allowing easier integration of
data from multiple labs, and less sensitive to polymorphisms in
transcript sequence that are common in highly polymorphic cancer
genomes. For these reasons, we have tailored ISOLATE’s statistical
model for HTS gene expression data.
ThesuccessfulapplicationofISOLATEorotherexpression-based
models will depend on the availability of expression proﬁles for a
wide range of human tissues, in order to consider them as potential
sitesoforigin.Withthecostsofhigh-throughputexpressionproﬁling
droppingquicklyandthenumberofstudiesusingthesetechnologies
to proﬁle tumors increases (Jones et al., 2008; Parsons et al., 2008),
soon it will be practical to collect a compendium of expression data
from many of the individual tissues of humans along with multiple
tumor samples, as is currently available for microarrays (see, e.g.
Su et al., 2004).
Molecular-based diagnostic tools for identifying cancer sites of
origin represent an important class of tools that can potentially
facilitate faster, more accurate diagnoses leading to the successful
identiﬁcation of primary sites. ISOLATE will be an invaluable tool
for exploring new, uncharacterized cancers of unknown primary
origin for which little expression data are available, or clinically
ambiguous samples for which more traditional models cannot
classify with high accuracy.
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